Category:Cannabinoids - Revision history

MDElliottMD: Category taxonomy ship: retag plant categories -> Plants

2026-05-22T00:37:55Z

Category taxonomy ship: retag plant categories -> Plants

← Older revision		Revision as of 00:37, 22 May 2026
Line 38:		Line 38:
	[[Category:MedCategoryFull]]		[[Category:MedCategoryFull]]
	[[Category:Pharmaceutical]]		[[Category:Pharmaceutical]]
	[[Category:~~Plant~~]]		[[Category:Plants]]

MDElliottMD: Phase 2 retag: add Pharmaceutical + Plant root parent (taxonomy restructure 2026-05-20)

2026-05-19T19:22:05Z

Phase 2 retag: add Pharmaceutical + Plant root parent (taxonomy restructure 2026-05-20)

← Older revision		Revision as of 19:22, 19 May 2026
Line 37:		Line 37:
	[[Category:MedCategory]]		[[Category:MedCategory]]
	[[Category:MedCategoryFull]]		[[Category:MedCategoryFull]]
			[[Category:Pharmaceutical]]
			[[Category:Plant]]

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:14Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 1:		Line 1:
	[[Cannabis]] is among the oldest plants used by humans as a medicine. Archaeological evidence places its use for intoxication at least 2,500 years ago — residue analysis of wooden braziers from the Jirzankal cemetery in the Pamir Mountains of western China, dated to around 500 BCE, found chemical traces consistent with the deliberate use of high-potency [[cannabis]].<ref name="ren2019">Ren M, Tang Z, Wu X, et al. The origins of cannabis smoking: chemical residue evidence from the first millennium BCE in the Pamirs. ''Sci Adv.'' 2019;5(6):eaaw1391. PMID 31206023.</ref> Written records of its medicinal use appear earlier still, in ancient China, Egypt, and Greece, and later across the Roman world.<ref name="crocq2020">Crocq MA. History of cannabis and the endocannabinoid system. ''Dialogues Clin Neurosci.'' 2020;22(3):223–228. PMID 33162765.</ref>		[[Cannabis]] is among the oldest plants used by humans as a medicine. Archaeological evidence places its use for intoxication at least 2,500 years ago, residue analysis of wooden braziers from the Jirzankal cemetery in the Pamir Mountains of western China, dated to around 500 BCE, found chemical traces consistent with the deliberate use of high-potency [[cannabis]].<ref name="ren2019">Ren M, Tang Z, Wu X, et al. The origins of cannabis smoking: chemical residue evidence from the first millennium BCE in the Pamirs. ''Sci Adv.'' 2019;5(6):eaaw1391. PMID 31206023.</ref> Written records of its medicinal use appear earlier still, in ancient China, Egypt, and Greece, and later across the Roman world.<ref name="crocq2020">Crocq MA. History of cannabis and the endocannabinoid system. ''Dialogues Clin Neurosci.'' 2020;22(3):223–228. PMID 33162765.</ref>

	In the nineteenth century, Western physicians in contact with Indian and Middle Eastern medicine — among them the Irish doctor William Brooke O'Shaughnessy — introduced [[cannabis]] preparations into European medical practice.<ref name="crocq2020"/> But the chemistry of the plant remained obscure for more than a century afterward, because its active constituents had never been isolated in pure form.		In the nineteenth century, Western physicians in contact with Indian and Middle Eastern medicine, among them the Irish doctor William Brooke O'Shaughnessy, introduced [[cannabis]] preparations into European medical practice.<ref name="crocq2020"/> But the chemistry of the plant remained obscure for more than a century afterward, because its active constituents had never been isolated in pure form.

	'''Cannabinoids''' are the family of compounds — found in the [[cannabis]] plant, produced naturally in the body, or made synthetically — that act on the body's cannabinoid signalling system. The term covers three overlapping groups: the '''phytocannabinoids''' of the plant (such as [[THC]] and [[Cannabidiol\|CBD]]), the '''endocannabinoids''' produced within the body, and a range of '''synthetic cannabinoids'''.		'''Cannabinoids''' are the family of compounds, found in the [[cannabis]] plant, produced naturally in the body, or made synthetically, that act on the body's cannabinoid signalling system. The term covers three overlapping groups: the '''phytocannabinoids''' of the plant (such as [[THC]] and [[Cannabidiol\|CBD]]), the '''endocannabinoids''' produced within the body, and a range of '''synthetic cannabinoids'''.

	{{PendellsCorner		{{PendellsCorner
Line 20:		Line 20:

	== Mechanisms ==		== Mechanisms ==
	Cannabinoids bind cannabinoid receptors — chiefly CB1 and CB2. CB1 is found at high density in the nervous system, and CB2 mainly in immune and peripheral tissues; [[THC]] binds both, and its binding at CB1 is widely associated with the intoxicating effects of [[cannabis]].<ref name="pertwee2006"/> Beyond this, the relationship between cannabinoid receptor binding and the many effects attributed to cannabinoids is an area of active research and should not be regarded as fully established: that a compound binds a receptor is one kind of finding; that this binding produces a particular clinical or behavioral effect is a separate inference. [[Cannabidiol\|CBD]] is a case in point — it has little affinity for CB1, and the purported mechanisms behind its reported effects remain under investigation.<ref name="pertwee2006"/>		Cannabinoids bind cannabinoid receptors, chiefly CB1 and CB2. CB1 is found at high density in the nervous system, and CB2 mainly in immune and peripheral tissues; [[THC]] binds both, and its binding at CB1 is widely associated with the intoxicating effects of [[cannabis]].<ref name="pertwee2006"/> Beyond this, the relationship between cannabinoid receptor binding and the many effects attributed to cannabinoids is an area of active research and should not be regarded as fully established: that a compound binds a receptor is one kind of finding; that this binding produces a particular clinical or behavioral effect is a separate inference. [[Cannabidiol\|CBD]] is a case in point, it has little affinity for CB1, and the purported mechanisms behind its reported effects remain under investigation.<ref name="pertwee2006"/>

	== Medical and legal status ==		== Medical and legal status ==
	Interest in the medical use of cannabinoids has grown substantially since the endocannabinoid system was described. Some cannabinoid medicines have received regulatory approval for specific uses — for example in certain forms of childhood epilepsy, and for nausea and appetite loss — while many other proposed uses remain under study.<ref name="crocq2020"/> The legal status of [[cannabis]] and cannabinoids varies widely between jurisdictions and has been changing rapidly in many countries.		Interest in the medical use of cannabinoids has grown substantially since the endocannabinoid system was described. Some cannabinoid medicines have received regulatory approval for specific uses, for example in certain forms of childhood epilepsy, and for nausea and appetite loss, while many other proposed uses remain under study.<ref name="crocq2020"/> The legal status of [[cannabis]] and cannabinoids varies widely between jurisdictions and has been changing rapidly in many countries.

	== Members ==		== Members ==
	The phytocannabinoids of the cannabis plant include [[THC]] (with regulatory-approved formulations [[dronabinol]] and the related [[nabilone]]) and [[Cannabidiol\|CBD]]. [[Nabiximols]] is a standardized cannabis extract approved in several jurisdictions for spasticity in multiple sclerosis. The synthetic cannabinoids — a wide and chemically varied group developed outside medicine, including [[JWH-018]], [[AB-FUBINACA]], and many others — have been encountered chiefly as illicit substances. The list is not exhaustive.		The phytocannabinoids of the cannabis plant include [[THC]] (with regulatory-approved formulations [[dronabinol]] and the related [[nabilone]]) and [[Cannabidiol\|CBD]]. [[Nabiximols]] is a standardized cannabis extract approved in several jurisdictions for spasticity in multiple sclerosis. The synthetic cannabinoids, a wide and chemically varied group developed outside medicine, including [[JWH-018]], [[AB-FUBINACA]], and many others, have been encountered chiefly as illicit substances. The list is not exhaustive.

	== Safety ==		== Safety ==
	Reported adverse effects vary by compound, dose, and route, and figures in the literature are population estimates that differ between studies. [[THC]] is associated with acute effects including anxiety, impaired short-term memory, and impaired coordination, and heavy or early use has been associated in observational research with mental-health risks, though the nature of that association continues to be debated. Synthetic cannabinoids — chemically varied and often far more potent at CB1 than [[THC]] — have been associated with a considerably higher rate of serious adverse effects. [[Cannabidiol\|CBD]] is generally reported to be well tolerated. Individual response is reported to vary considerably between people.		Reported adverse effects vary by compound, dose, and route, and figures in the literature are population estimates that differ between studies. [[THC]] is associated with acute effects including anxiety, impaired short-term memory, and impaired coordination, and heavy or early use has been associated in observational research with mental-health risks, though the nature of that association continues to be debated. Synthetic cannabinoids, chemically varied and often far more potent at CB1 than [[THC]], have been associated with a considerably higher rate of serious adverse effects. [[Cannabidiol\|CBD]] is generally reported to be well tolerated. Individual response is reported to vary considerably between people.

	== References ==		== References ==

MDElliottMD: Pipe lead CBD -> CBD to match page convention and resolve redlink

2026-05-18T00:31:03Z

Pipe lead CBD -> CBD to match page convention and resolve redlink

← Older revision		Revision as of 00:31, 18 May 2026
Line 3:		Line 3:
	In the nineteenth century, Western physicians in contact with Indian and Middle Eastern medicine — among them the Irish doctor William Brooke O'Shaughnessy — introduced [[cannabis]] preparations into European medical practice.<ref name="crocq2020"/> But the chemistry of the plant remained obscure for more than a century afterward, because its active constituents had never been isolated in pure form.		In the nineteenth century, Western physicians in contact with Indian and Middle Eastern medicine — among them the Irish doctor William Brooke O'Shaughnessy — introduced [[cannabis]] preparations into European medical practice.<ref name="crocq2020"/> But the chemistry of the plant remained obscure for more than a century afterward, because its active constituents had never been isolated in pure form.

	'''Cannabinoids''' are the family of compounds — found in the [[cannabis]] plant, produced naturally in the body, or made synthetically — that act on the body's cannabinoid signalling system. The term covers three overlapping groups: the '''phytocannabinoids''' of the plant (such as [[THC]] and [[CBD]]), the '''endocannabinoids''' produced within the body, and a range of '''synthetic cannabinoids'''.		'''Cannabinoids''' are the family of compounds — found in the [[cannabis]] plant, produced naturally in the body, or made synthetically — that act on the body's cannabinoid signalling system. The term covers three overlapping groups: the '''phytocannabinoids''' of the plant (such as [[THC]] and [[Cannabidiol\|CBD]]), the '''endocannabinoids''' produced within the body, and a range of '''synthetic cannabinoids'''.

	{{PendellsCorner		{{PendellsCorner

MDElliottMD: Back-fill Category:Medicines wikilinks across prose (Cannabis, THC, CBD)

2026-05-18T00:24:17Z

Back-fill Category:Medicines wikilinks across prose (Cannabis, THC, CBD)

← Older revision		Revision as of 00:24, 18 May 2026
Line 1:		Line 1:
	Cannabis is among the oldest plants used by humans as a medicine. Archaeological evidence places its use for intoxication at least 2,500 years ago — residue analysis of wooden braziers from the Jirzankal cemetery in the Pamir Mountains of western China, dated to around 500 BCE, found chemical traces consistent with the deliberate use of high-potency cannabis.<ref name="ren2019">Ren M, Tang Z, Wu X, et al. The origins of cannabis smoking: chemical residue evidence from the first millennium BCE in the Pamirs. ''Sci Adv.'' 2019;5(6):eaaw1391. PMID 31206023.</ref> Written records of its medicinal use appear earlier still, in ancient China, Egypt, and Greece, and later across the Roman world.<ref name="crocq2020">Crocq MA. History of cannabis and the endocannabinoid system. ''Dialogues Clin Neurosci.'' 2020;22(3):223–228. PMID 33162765.</ref>		[[Cannabis]] is among the oldest plants used by humans as a medicine. Archaeological evidence places its use for intoxication at least 2,500 years ago — residue analysis of wooden braziers from the Jirzankal cemetery in the Pamir Mountains of western China, dated to around 500 BCE, found chemical traces consistent with the deliberate use of high-potency [[cannabis]].<ref name="ren2019">Ren M, Tang Z, Wu X, et al. The origins of cannabis smoking: chemical residue evidence from the first millennium BCE in the Pamirs. ''Sci Adv.'' 2019;5(6):eaaw1391. PMID 31206023.</ref> Written records of its medicinal use appear earlier still, in ancient China, Egypt, and Greece, and later across the Roman world.<ref name="crocq2020">Crocq MA. History of cannabis and the endocannabinoid system. ''Dialogues Clin Neurosci.'' 2020;22(3):223–228. PMID 33162765.</ref>

	In the nineteenth century, Western physicians in contact with Indian and Middle Eastern medicine — among them the Irish doctor William Brooke O'Shaughnessy — introduced cannabis preparations into European medical practice.<ref name="crocq2020"/> But the chemistry of the plant remained obscure for more than a century afterward, because its active constituents had never been isolated in pure form.		In the nineteenth century, Western physicians in contact with Indian and Middle Eastern medicine — among them the Irish doctor William Brooke O'Shaughnessy — introduced [[cannabis]] preparations into European medical practice.<ref name="crocq2020"/> But the chemistry of the plant remained obscure for more than a century afterward, because its active constituents had never been isolated in pure form.

	'''Cannabinoids''' are the family of compounds — found in the cannabis plant, produced naturally in the body, or made synthetically — that act on the body's cannabinoid signalling system. The term covers three overlapping groups: the '''phytocannabinoids''' of the plant (such as [[THC]] and [[CBD]]), the '''endocannabinoids''' produced within the body, and a range of '''synthetic cannabinoids'''.		'''Cannabinoids''' are the family of compounds — found in the [[cannabis]] plant, produced naturally in the body, or made synthetically — that act on the body's cannabinoid signalling system. The term covers three overlapping groups: the '''phytocannabinoids''' of the plant (such as [[THC]] and [[CBD]]), the '''endocannabinoids''' produced within the body, and a range of '''synthetic cannabinoids'''.

	{{PendellsCorner		{{PendellsCorner
Line 12:		Line 12:

	== The isolation of THC ==		== The isolation of THC ==
	The modern science of cannabinoids is usually dated to 1964, when Raphael Mechoulam and Yechiel Gaoni, then at the Weizmann Institute of Science in Rehovot, Israel, first isolated delta-9-tetrahydrocannabinol (THC) in pure form and determined its structure, identifying it as the principal psychoactive constituent of cannabis.<ref name="gaoni1964">Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. ''J Am Chem Soc.'' 1964;86(8):1646–1647.</ref><ref name="mechoulam2023">Mechoulam R. A delightful trip along the pathway of cannabinoid and endocannabinoid chemistry and pharmacology. ''Annu Rev Pharmacol Toxicol.'' 2023;63:1–13. PMID 35850522.</ref> The related compound cannabidiol (CBD) had been described earlier, and its structure was also established by Mechoulam's group in the early 1960s. This work opened cannabis to systematic pharmacological study; more than a hundred phytocannabinoids have since been identified, though only some are psychoactive.<ref name="pertwee2006">Pertwee RG. Cannabinoid pharmacology: the first 66 years. ''Br J Pharmacol.'' 2006;147(Suppl 1):S163–S171. PMID 16402100.</ref>		The modern science of cannabinoids is usually dated to 1964, when Raphael Mechoulam and Yechiel Gaoni, then at the Weizmann Institute of Science in Rehovot, Israel, first isolated delta-9-tetrahydrocannabinol ([[THC]]) in pure form and determined its structure, identifying it as the principal psychoactive constituent of [[cannabis]].<ref name="gaoni1964">Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. ''J Am Chem Soc.'' 1964;86(8):1646–1647.</ref><ref name="mechoulam2023">Mechoulam R. A delightful trip along the pathway of cannabinoid and endocannabinoid chemistry and pharmacology. ''Annu Rev Pharmacol Toxicol.'' 2023;63:1–13. PMID 35850522.</ref> The related compound [[cannabidiol]] ([[Cannabidiol\|CBD]]) had been described earlier, and its structure was also established by Mechoulam's group in the early 1960s. This work opened [[cannabis]] to systematic pharmacological study; more than a hundred phytocannabinoids have since been identified, though only some are psychoactive.<ref name="pertwee2006">Pertwee RG. Cannabinoid pharmacology: the first 66 years. ''Br J Pharmacol.'' 2006;147(Suppl 1):S163–S171. PMID 16402100.</ref>

	== Discovery of the endocannabinoid system ==		== Discovery of the endocannabinoid system ==
	A second major chapter opened in the late 1980s and 1990s. In 1988, Allyn Howlett and William Devane identified specific binding sites for THC in rat brain tissue. The first cannabinoid receptor, CB1, was cloned in 1990 by Lisa Matsuda and colleagues at the U.S. National Institute of Mental Health, and a second, CB2, was cloned in 1993 by Sean Munro's group in Cambridge.<ref name="crocq2020"/>		A second major chapter opened in the late 1980s and 1990s. In 1988, Allyn Howlett and William Devane identified specific binding sites for [[THC]] in rat brain tissue. The first cannabinoid receptor, CB1, was cloned in 1990 by Lisa Matsuda and colleagues at the U.S. National Institute of Mental Health, and a second, CB2, was cloned in 1993 by Sean Munro's group in Cambridge.<ref name="crocq2020"/>

	The existence of receptors implied that the body produces its own cannabinoid-like signalling molecules. In 1992, a group including William Devane, Lumír Hanuš, and Raphael Mechoulam isolated the first such molecule and named it anandamide, after the Sanskrit word for bliss; a second, 2-arachidonoylglycerol (2-AG), was characterized soon afterward.<ref name="crocq2020"/> Together the receptors, the endocannabinoids, and the enzymes that build and break them down are referred to as the endocannabinoid system.		The existence of receptors implied that the body produces its own cannabinoid-like signalling molecules. In 1992, a group including William Devane, Lumír Hanuš, and Raphael Mechoulam isolated the first such molecule and named it anandamide, after the Sanskrit word for bliss; a second, 2-arachidonoylglycerol (2-AG), was characterized soon afterward.<ref name="crocq2020"/> Together the receptors, the endocannabinoids, and the enzymes that build and break them down are referred to as the endocannabinoid system.

	== Mechanisms ==		== Mechanisms ==
	Cannabinoids bind cannabinoid receptors — chiefly CB1 and CB2. CB1 is found at high density in the nervous system, and CB2 mainly in immune and peripheral tissues; THC binds both, and its binding at CB1 is widely associated with the intoxicating effects of cannabis.<ref name="pertwee2006"/> Beyond this, the relationship between cannabinoid receptor binding and the many effects attributed to cannabinoids is an area of active research and should not be regarded as fully established: that a compound binds a receptor is one kind of finding; that this binding produces a particular clinical or behavioral effect is a separate inference. CBD is a case in point — it has little affinity for CB1, and the purported mechanisms behind its reported effects remain under investigation.<ref name="pertwee2006"/>		Cannabinoids bind cannabinoid receptors — chiefly CB1 and CB2. CB1 is found at high density in the nervous system, and CB2 mainly in immune and peripheral tissues; [[THC]] binds both, and its binding at CB1 is widely associated with the intoxicating effects of [[cannabis]].<ref name="pertwee2006"/> Beyond this, the relationship between cannabinoid receptor binding and the many effects attributed to cannabinoids is an area of active research and should not be regarded as fully established: that a compound binds a receptor is one kind of finding; that this binding produces a particular clinical or behavioral effect is a separate inference. [[Cannabidiol\|CBD]] is a case in point — it has little affinity for CB1, and the purported mechanisms behind its reported effects remain under investigation.<ref name="pertwee2006"/>

	== Medical and legal status ==		== Medical and legal status ==
	Interest in the medical use of cannabinoids has grown substantially since the endocannabinoid system was described. Some cannabinoid medicines have received regulatory approval for specific uses — for example in certain forms of childhood epilepsy, and for nausea and appetite loss — while many other proposed uses remain under study.<ref name="crocq2020"/> The legal status of cannabis and cannabinoids varies widely between jurisdictions and has been changing rapidly in many countries.		Interest in the medical use of cannabinoids has grown substantially since the endocannabinoid system was described. Some cannabinoid medicines have received regulatory approval for specific uses — for example in certain forms of childhood epilepsy, and for nausea and appetite loss — while many other proposed uses remain under study.<ref name="crocq2020"/> The legal status of [[cannabis]] and cannabinoids varies widely between jurisdictions and has been changing rapidly in many countries.

	== Members ==		== Members ==
Line 29:		Line 29:

	== Safety ==		== Safety ==
	Reported adverse effects vary by compound, dose, and route, and figures in the literature are population estimates that differ between studies. THC is associated with acute effects including anxiety, impaired short-term memory, and impaired coordination, and heavy or early use has been associated in observational research with mental-health risks, though the nature of that association continues to be debated. Synthetic cannabinoids — chemically varied and often far more potent at CB1 than THC — have been associated with a considerably higher rate of serious adverse effects. CBD is generally reported to be well tolerated. Individual response is reported to vary considerably between people.		Reported adverse effects vary by compound, dose, and route, and figures in the literature are population estimates that differ between studies. [[THC]] is associated with acute effects including anxiety, impaired short-term memory, and impaired coordination, and heavy or early use has been associated in observational research with mental-health risks, though the nature of that association continues to be debated. Synthetic cannabinoids — chemically varied and often far more potent at CB1 than [[THC]] — have been associated with a considerably higher rate of serious adverse effects. [[Cannabidiol\|CBD]] is generally reported to be well tolerated. Individual response is reported to vary considerably between people.

	== References ==		== References ==

MDElliottMD: Add manual Members section (auto-list hidden on MedCategoryFull pages)

2026-05-17T02:35:43Z

Add manual Members section (auto-list hidden on MedCategoryFull pages)

← Older revision		Revision as of 02:35, 17 May 2026
Line 24:		Line 24:
	== Medical and legal status ==		== Medical and legal status ==
	Interest in the medical use of cannabinoids has grown substantially since the endocannabinoid system was described. Some cannabinoid medicines have received regulatory approval for specific uses — for example in certain forms of childhood epilepsy, and for nausea and appetite loss — while many other proposed uses remain under study.<ref name="crocq2020"/> The legal status of cannabis and cannabinoids varies widely between jurisdictions and has been changing rapidly in many countries.		Interest in the medical use of cannabinoids has grown substantially since the endocannabinoid system was described. Some cannabinoid medicines have received regulatory approval for specific uses — for example in certain forms of childhood epilepsy, and for nausea and appetite loss — while many other proposed uses remain under study.<ref name="crocq2020"/> The legal status of cannabis and cannabinoids varies widely between jurisdictions and has been changing rapidly in many countries.

			== Members ==
			The phytocannabinoids of the cannabis plant include [[THC]] (with regulatory-approved formulations [[dronabinol]] and the related [[nabilone]]) and [[Cannabidiol\|CBD]]. [[Nabiximols]] is a standardized cannabis extract approved in several jurisdictions for spasticity in multiple sclerosis. The synthetic cannabinoids — a wide and chemically varied group developed outside medicine, including [[JWH-018]], [[AB-FUBINACA]], and many others — have been encountered chiefly as illicit substances. The list is not exhaustive.

	== Safety ==		== Safety ==

MDElliottMD: Add MedCategoryFull marker to enable scoped auto-list hide

2026-05-17T02:09:10Z

Add MedCategoryFull marker to enable scoped auto-list hide

← Older revision		Revision as of 02:09, 17 May 2026
Line 33:		Line 33:

	[[Category:MedCategory]]		[[Category:MedCategory]]
			[[Category:MedCategoryFull]]

MDElliottMD: Drop voice=Prose from PendellsCorner block

2026-05-17T00:55:28Z

Drop voice=Prose from PendellsCorner block

← Older revision		Revision as of 00:55, 17 May 2026
Line 9:		Line 9:
	\| volume = Poeia		\| volume = Poeia
	\| page = 180		\| page = 180
	~~\| voice = Prose~~
	}}		}}

MDElliottMD: Replace stub with full Cannabinoids category page

2026-05-17T00:41:27Z

Replace stub with full Cannabinoids category page

← Older revision		Revision as of 00:41, 17 May 2026
Line 1:		Line 1:
	~~This category~~ groups ~~medicines belonging to~~ the [[~~Classes\|Cannabinoids~~]] ~~class. See~~ [[~~Classes~~]] for the ~~full taxonomy~~.		Cannabis is among the oldest plants used by humans as a medicine. Archaeological evidence places its use for intoxication at least 2,500 years ago — residue analysis of wooden braziers from the Jirzankal cemetery in the Pamir Mountains of western China, dated to around 500 BCE, found chemical traces consistent with the deliberate use of high-potency cannabis.<ref name="ren2019">Ren M, Tang Z, Wu X, et al. The origins of cannabis smoking: chemical residue evidence from the first millennium BCE in the Pamirs. ''Sci Adv.'' 2019;5(6):eaaw1391. PMID 31206023.</ref> Written records of its medicinal use appear earlier still, in ancient China, Egypt, and Greece, and later across the Roman world.<ref name="crocq2020">Crocq MA. History of cannabis and the endocannabinoid system. ''Dialogues Clin Neurosci.'' 2020;22(3):223–228. PMID 33162765.</ref>

			In the nineteenth century, Western physicians in contact with Indian and Middle Eastern medicine — among them the Irish doctor William Brooke O'Shaughnessy — introduced cannabis preparations into European medical practice.<ref name="crocq2020"/> But the chemistry of the plant remained obscure for more than a century afterward, because its active constituents had never been isolated in pure form.

			'''Cannabinoids''' are the family of compounds — found in the cannabis plant, produced naturally in the body, or made synthetically — that act on the body's cannabinoid signalling system. The term covers three overlapping groups: the '''phytocannabinoids''' of the plant (such as [[THC]] and [[CBD]]), the '''endocannabinoids''' produced within the body, and a range of '''synthetic cannabinoids'''.

			{{PendellsCorner
			\| quote = Cannabis may be mankind's first cultivated plant, but it has never lost its wildness.
			\| volume = Poeia
			\| page = 180
			\| voice = Prose
			}}

			== The isolation of THC ==
			The modern science of cannabinoids is usually dated to 1964, when Raphael Mechoulam and Yechiel Gaoni, then at the Weizmann Institute of Science in Rehovot, Israel, first isolated delta-9-tetrahydrocannabinol (THC) in pure form and determined its structure, identifying it as the principal psychoactive constituent of cannabis.<ref name="gaoni1964">Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. ''J Am Chem Soc.'' 1964;86(8):1646–1647.</ref><ref name="mechoulam2023">Mechoulam R. A delightful trip along the pathway of cannabinoid and endocannabinoid chemistry and pharmacology. ''Annu Rev Pharmacol Toxicol.'' 2023;63:1–13. PMID 35850522.</ref> The related compound cannabidiol (CBD) had been described earlier, and its structure was also established by Mechoulam's group in the early 1960s. This work opened cannabis to systematic pharmacological study; more than a hundred phytocannabinoids have since been identified, though only some are psychoactive.<ref name="pertwee2006">Pertwee RG. Cannabinoid pharmacology: the first 66 years. ''Br J Pharmacol.'' 2006;147(Suppl 1):S163–S171. PMID 16402100.</ref>

			== Discovery of the endocannabinoid system ==
			A second major chapter opened in the late 1980s and 1990s. In 1988, Allyn Howlett and William Devane identified specific binding sites for THC in rat brain tissue. The first cannabinoid receptor, CB1, was cloned in 1990 by Lisa Matsuda and colleagues at the U.S. National Institute of Mental Health, and a second, CB2, was cloned in 1993 by Sean Munro's group in Cambridge.<ref name="crocq2020"/>

			The existence of receptors implied that the body produces its own cannabinoid-like signalling molecules. In 1992, a group including William Devane, Lumír Hanuš, and Raphael Mechoulam isolated the first such molecule and named it anandamide, after the Sanskrit word for bliss; a second, 2-arachidonoylglycerol (2-AG), was characterized soon afterward.<ref name="crocq2020"/> Together the receptors, the endocannabinoids, and the enzymes that build and break them down are referred to as the endocannabinoid system.

			== Mechanisms ==
			Cannabinoids bind cannabinoid receptors — chiefly CB1 and CB2. CB1 is found at high density in the nervous system, and CB2 mainly in immune and peripheral tissues; THC binds both, and its binding at CB1 is widely associated with the intoxicating effects of cannabis.<ref name="pertwee2006"/> Beyond this, the relationship between cannabinoid receptor binding and the many effects attributed to cannabinoids is an area of active research and should not be regarded as fully established: that a compound binds a receptor is one kind of finding; that this binding produces a particular clinical or behavioral effect is a separate inference. CBD is a case in point — it has little affinity for CB1, and the purported mechanisms behind its reported effects remain under investigation.<ref name="pertwee2006"/>

			== Medical and legal status ==
			Interest in the medical use of cannabinoids has grown substantially since the endocannabinoid system was described. Some cannabinoid medicines have received regulatory approval for specific uses — for example in certain forms of childhood epilepsy, and for nausea and appetite loss — while many other proposed uses remain under study.<ref name="crocq2020"/> The legal status of cannabis and cannabinoids varies widely between jurisdictions and has been changing rapidly in many countries.

			== Safety ==
			Reported adverse effects vary by compound, dose, and route, and figures in the literature are population estimates that differ between studies. THC is associated with acute effects including anxiety, impaired short-term memory, and impaired coordination, and heavy or early use has been associated in observational research with mental-health risks, though the nature of that association continues to be debated. Synthetic cannabinoids — chemically varied and often far more potent at CB1 than THC — have been associated with a considerably higher rate of serious adverse effects. CBD is generally reported to be well tolerated. Individual response is reported to vary considerably between people.

			== References ==

			<references/>

	[[Category:MedCategory]]		[[Category:MedCategory]]

MDElliottMD: Pharmacopedia: seed interaction class category

2026-05-14T01:10:03Z

Pharmacopedia: seed interaction class category

New page

This category groups medicines belonging to the [[Classes|Cannabinoids]] class. See [[Classes]] for the full taxonomy.

[[Category:MedCategory]]